Sun Pharma Advanced Research Company Limited — Updates, 19-05-2026: General Updates

SPARC's licensing partner Ocuvex received an FDA Complete Response Letter for PDP-716 NDA, delaying approval. The issue stems from manufacturing facility inspection findings, not the drug's efficacy or safety.